Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.
No Thumbnail Available
Identifiers
Date
2018-10-10
Authors
Dickinson, Michael
Cherif, Honar
Fenaux, Pierre
Mittelman, Moshe
Verma, Amit
Portella, Maria Socorro O
Burgess, Paul
Ramos, Pedro Marques
Choi, Jeea
Platzbecker, Uwe
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Azacitidine treatment of myelodysplastic syndromes (MDSs) generally exacerbates thrombocytopenia during the first treatment cycles. A Study of Eltrombopag in Myelodysplastic Syndromes Receiving Azacitidine (SUPPORT), a phase 3, randomized, double-blind, placebo-controlled study, investigated the platelet supportive effects of eltrombopag given concomitantly with azacitidine. International Prognostic Scoring System intermediate-1, intermediate-2, or high-risk MDS patients with baseline platelets
Description
MeSH Terms
Adult
Aged
Aged, 80 and over
Azacitidine
Benzoates
Double-Blind Method
Female
Humans
Hydrazines
Male
Middle Aged
Myelodysplastic Syndromes
Platelet Transfusion
Pyrazoles
Risk Factors
Thrombocytopenia
Aged
Aged, 80 and over
Azacitidine
Benzoates
Double-Blind Method
Female
Humans
Hydrazines
Male
Middle Aged
Myelodysplastic Syndromes
Platelet Transfusion
Pyrazoles
Risk Factors
Thrombocytopenia